SCHEMBL18285285

SCHEMBL18285285

CC(C)(C)NC(=O)c1cc(-c2ccc(F)cc2)cc(-n2ccnc2C2CC2)c1

nearest known ligand 0.39

Predicted protein targets (top 18)

geneUniProtsupporting neighboursconfidence
P2RY14 Q15391 1/20 0.39
CNR2 P34972 2/20 0.38
CNR1 P21554 1/20 0.38
TTK P33981 1/20 0.36
SCN9A Q15858 1/20 0.36
LMNA P02545 1/20 0.36
MAPT P10636 1/20 0.36
THRB P10828 1/20 0.36
HTR2B P41595 1/20 0.35
SMN1; SMN2 Q16637 1/20 0.35
FGFR1 P11362 1/20 0.35
ANO1 Q5XXA6 1/20 0.35
HPGDS O60760 1/20 0.35
PIP5K1C O60331 1/20 0.35
PIK3CA P42336 1/20 0.35
ATR Q13535 1/20 0.35
WDR5 P61964 1/20 0.34
RIPK1 Q13546 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL18285346 0.92 WDR5 (0.36) CNR2CNR1TTKHTR2BSMN1; SMN2
SCHEMBL18285328 0.90 CNR1 (0.40) P2RY14CNR2CNR1LMNAANO1
SCHEMBL20921547 0.88 P2RY14 (0.36) P2RY14CNR2LMNAWDR5RIPK1
SCHEMBL18285367 0.84 RAF1 (0.43) P2RY14LMNAMAPTTHRBFGFR1
SCHEMBL18285309 0.83 P2RY14 (0.41) P2RY14CNR2LMNAMAPTTHRB
SCHEMBL18285310 0.83 LMNA (0.35) P2RY14CNR2LMNAWDR5
SCHEMBL18285343 0.82 P2RY14 (0.40) P2RY14CNR2LMNAMAPTTHRB
SCHEMBL18285324 0.82 ANO1 (0.35) P2RY14CNR1LMNAANO1WDR5
SCHEMBL18389517 0.82 HPGDS (0.39) CNR2CNR1SCN9ALMNAMAPT
SCHEMBL18285360 0.82 P2RY14 (0.40) P2RY14TTKLMNAMAPTTHRB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-107531642-B Imidazole derivatives 豪夫迈·罗氏有限公司 2021-06-22 CN claimed
EP-3303299-B1 IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-24 EP claimed
EP-3303299-A1 IMIDAZOLE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-04-11 EP claimed
WO-2016193235-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-12-08 WO claimed
CN-107531642-B Imidazole derivatives 豪夫迈·罗氏有限公司 2021-06-22 CN disclosed
EP-3303299-B1 IMIDAZOLE DERIVATIVES HOFFMANN LA ROCHE (CH) 2019-04-24 EP disclosed
US-10029989-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2018-07-24 US disclosed
US-10029989-B2 Imidazole derivatives HOFFMANN-LA ROCHE INC. (US) 2018-07-24 US disclosed
US-20180118692-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 US disclosed
US-20180118692-A1 IMIDAZOLE DERIVATIVES HOFFMANN-LA ROCHE INC. (US) 2018-05-03 US disclosed
EP-3303299-A1 IMIDAZOLE DERIVATIVES H. Hoffnabb-La Roche Ag (CH) 2018-04-11 EP disclosed
WO-2016193235-A1 IMIDAZOLE DERIVATIVES F. HOFFMANN-LA ROCHE AG (CH) 2016-12-08 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20180118692-A1 IMIDAZOLE DERIVATIVES DRD3, GABRR3, DRD4 P2RY14 3572/4885CNR2 590/4885CNR1 214/4885
US-10029989-B2 Imidazole derivatives DRD3, GABRR3, DRD4 P2RY14 3572/4885CNR2 590/4885CNR1 214/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.